Alector prices $75M stock offering at a premium to fund neurodegeneration pipeline
What's the deal? Alector, a South San Francisco biotechnology company, priced an underwritten offering of 36,600,000 common shares at $2.05 each, for gross proceeds of $75,030,000. The price marks roughly a 7.3% premium over the stock's October 15 close. New and existing investors are participating, including TCGXDealroom has a profile for this one. Try Dealroom →, BVF PartnersDealroom has a profile for this one. Try Dealroom →, ADAR1 Capital ManagementDealroom has a profile for this one. Try Dealroom →, and Deep Track CapitalDealroom has a profile for this one. Try Dealroom →.
Why now? The Nasdaq-listed company (ALEC) is tapping public markets to fuel a pipeline aimed at neurodegenerative diseases such as Alzheimer's and Parkinson's. The offering is expected to close on or about October 19, 2026.
What's the endgame? Alector develops therapies built on genetics, immunology, and neuroscience, with candidates designed to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. It is also advancing the Alector Brain Carrier, a proprietary blood-brain barrier platform meant to deliver drugs deeper into the brain at lower doses.
Where the money goes: Alector plans to use the net proceeds for general corporate purposes, which may include research, development, and manufacturing of its product candidates, working capital, and acquisitions or strategic transactions.
Morgan Stanley and BTIGDealroom has a profile for this one. Try Dealroom → are acting as joint lead book-running managers. The shares are being offered under a shelf registration statement previously declared effective by the Securities and Exchange Commission.
The signal: At $75 million, the raise sits in the upper range of its class — around the 70th percentile for deal size — a notable vote of confidence for a clinical-stage biotech pricing shares above market. Backing from specialist healthcare funds signals investor appetite to keep funding high-risk neurodegeneration bets.
Read more: marketscreener.com
Image credit: Generated with Gemini
